CN100545264C - 一种重组人角质细胞生长因子的生产方法 - Google Patents
一种重组人角质细胞生长因子的生产方法 Download PDFInfo
- Publication number
- CN100545264C CN100545264C CNB2005100854968A CN200510085496A CN100545264C CN 100545264 C CN100545264 C CN 100545264C CN B2005100854968 A CNB2005100854968 A CN B2005100854968A CN 200510085496 A CN200510085496 A CN 200510085496A CN 100545264 C CN100545264 C CN 100545264C
- Authority
- CN
- China
- Prior art keywords
- kgf
- leu
- growth factor
- gst
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000010261 cell growth Effects 0.000 title claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- 230000004927 fusion Effects 0.000 claims abstract description 34
- 241000894006 Bacteria Species 0.000 claims abstract description 25
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 claims abstract description 19
- 102000057239 human FGF7 Human genes 0.000 claims abstract description 19
- 150000001413 amino acids Chemical class 0.000 claims abstract description 16
- 108010013369 Enteropeptidase Proteins 0.000 claims abstract description 14
- 102100029727 Enteropeptidase Human genes 0.000 claims abstract description 12
- 239000013604 expression vector Substances 0.000 claims abstract description 12
- 238000010353 genetic engineering Methods 0.000 claims abstract description 11
- 238000011097 chromatography purification Methods 0.000 claims abstract description 5
- 238000000855 fermentation Methods 0.000 claims abstract description 5
- 230000004151 fermentation Effects 0.000 claims abstract description 5
- 230000000968 intestinal effect Effects 0.000 claims abstract description 5
- 238000000926 separation method Methods 0.000 claims abstract description 5
- 108091026890 Coding region Proteins 0.000 claims abstract description 4
- 238000005520 cutting process Methods 0.000 claims abstract description 4
- 238000000746 purification Methods 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 6
- 229920002684 Sepharose Polymers 0.000 claims description 6
- 108090000190 Thrombin Proteins 0.000 claims description 6
- 229960002897 heparin Drugs 0.000 claims description 6
- 229920000669 heparin Polymers 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 229960004072 thrombin Drugs 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 18
- 108010070675 Glutathione transferase Proteins 0.000 abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 6
- 229920001184 polypeptide Polymers 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 5
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 abstract description 3
- 238000005215 recombination Methods 0.000 abstract description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 49
- 102000005720 Glutathione transferase Human genes 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 102220023257 rs387907546 Human genes 0.000 description 4
- 238000005267 amalgamation Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 102220369447 c.1352G>A Human genes 0.000 description 2
- 102220369445 c.668T>C Human genes 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 102220023258 rs387907548 Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 231100000652 hormesis Toxicity 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000003946 protein process Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100854968A CN100545264C (zh) | 2005-07-22 | 2005-07-22 | 一种重组人角质细胞生长因子的生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100854968A CN100545264C (zh) | 2005-07-22 | 2005-07-22 | 一种重组人角质细胞生长因子的生产方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1766107A CN1766107A (zh) | 2006-05-03 |
CN100545264C true CN100545264C (zh) | 2009-09-30 |
Family
ID=36742224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100854968A Expired - Fee Related CN100545264C (zh) | 2005-07-22 | 2005-07-22 | 一种重组人角质细胞生长因子的生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100545264C (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101721683B (zh) * | 2009-11-10 | 2015-06-24 | 苏州金盟生物技术有限公司 | 人角质细胞生长因子1在制备治疗肛裂的药物中的应用 |
CN102242124B (zh) * | 2010-05-10 | 2013-05-22 | 齐鲁制药有限公司 | 改造的角化细胞生长因子基因及其在酵母中的表达 |
CN103952427A (zh) * | 2014-05-11 | 2014-07-30 | 浙江大学 | 人***瘤病毒6bE7蛋白表达及应用 |
CN104059933A (zh) * | 2014-05-11 | 2014-09-24 | 浙江大学 | 人***瘤病毒11e7蛋白表达及应用 |
CN106226511B (zh) * | 2016-07-28 | 2018-04-06 | 苏州金盟生物技术有限公司 | 一种重组人角质细胞生长因子生物学活性检测方法 |
CN109456399A (zh) * | 2017-09-06 | 2019-03-12 | 山东益华生物科技有限公司 | 植物作为宿主在表达角质细胞生长因子中的应用 |
KR20210138014A (ko) * | 2019-02-24 | 2021-11-18 | 온코시미스 바이오테크 프라이빗 리미티드 | 박테리아에 의한 재조합 glp-1 펩타이드의 연속 생성 방법 |
-
2005
- 2005-07-22 CN CNB2005100854968A patent/CN100545264C/zh not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
角质细胞生长因子在大肠杆菌中的表达、纯化及生物学活性研究. 黄新强.中国优秀硕士学位论文全文数据库. 2002 |
角质细胞生长因子在大肠杆菌中的表达、纯化及生物学活性研究. 黄新强.中国优秀硕士学位论文全文数据库. 2002 * |
重组人角质细胞生长因子-2基因的克隆和表达. 王金凤等.军事医学科学院院刊,第1期. 2004 |
重组人角质细胞生长因子-2基因的克隆和表达. 王金凤等.军事医学科学院院刊,第1期. 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN1766107A (zh) | 2006-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100545264C (zh) | 一种重组人角质细胞生长因子的生产方法 | |
CN110845603B (zh) | 人胶原蛋白17型多肽、其生产方法和用途 | |
AU648670B2 (en) | A-C-B Proinsulin, method of manufacturing and using same, and intermediates in insulin production | |
CN100564517C (zh) | 一种蝎抗神经胶质瘤肽及其制备方法和应用 | |
CN108912221A (zh) | 用于生产重组融合蛋白的辅助蛋白、编码基因、重组融合蛋白、重组表达载体及制备方法 | |
CN110724187B (zh) | 一种高效表达利拉鲁肽前体的重组工程菌及其应用 | |
CN101240033B (zh) | 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法 | |
CN101514229B (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物 | |
CN107353346A (zh) | 一种由猪白蛋白与猪干扰素γ组成的融合蛋白及其制备方法和一种重组猪长效干扰素γ | |
CN101875699B (zh) | 人表皮生长因子和金属硫蛋白的融合蛋白及其制备方法和应用 | |
CN100528899C (zh) | 含有肽载体和表皮生长因子的融合蛋白和核酸及其用途 | |
CN101434954A (zh) | 中华蜜蜂王浆主蛋白AccMRJP7基因及其编码蛋白 | |
CN101671390B (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 | |
CN113372452B (zh) | 一种细粒棘球绦虫重组蛋白CTLA4-IgV-EgG1Y162及其应用 | |
CN100418983C (zh) | 人胰高血糖素相关肽-2类似物 | |
CN102391377B (zh) | 一种可诱导和激活癌靶向t细胞的融合蛋白及制备方法及用途 | |
CN101897953B (zh) | 无创性高穿透性表皮生长因子及其应用 | |
CN110305887A (zh) | 抗真菌肽Drosomycin、制备方法及其应用 | |
CN101880327A (zh) | 蝎镇痛抗肿瘤缬精甘肽融合体及其获得方法 | |
CN100503826C (zh) | 一种重组人血小板衍生生长因子及其编码基因与表达方法 | |
CN100465272C (zh) | 重组东亚马氏钳蝎毒rBmKaIT1的基因工程 | |
KR100729830B1 (ko) | 페너트라틴을 이용하여 단백질의 세포투과를 증진시키는대장균용발현벡터 | |
CN101775404A (zh) | 一种原核表达体系高表达碱性蛋白的方法 | |
CN1313900A (zh) | 一种新的人溶菌酶基因、其编码的多肽及制备方法 | |
CN101481420B (zh) | 一种杂合抗菌肽ca-ma及其重组表达方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Min Hui Document name: Notice of conformity |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SUZHOU JINMENG BIOTECHNOLOGY CO., LTD. Effective date: 20110829 Owner name: CHENGDU JINKAI BIOTECHNOLOGY CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610041 CHENGDU, SICHUAN PROVINCE TO: 215425 SUZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110829 Address after: Shaxi town of Suzhou City, Jiangsu province 215425 Guizhuang Xiangtang High-tech Industrial Park Co-patentee after: CHENGDU JINKAI BIOLOGICAL TECHNOLOGY Co.,Ltd. Patentee after: SUZHOU GENEMEN BIOTECH Co.,Ltd. Address before: 610041 doctor's Pioneer Park, Chengdu hi tech Zone, Sichuan Patentee before: CHENGDU ZHITIAN BIOENGINEERING Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Shaxi town of Suzhou City, Jiangsu province 215425 Guizhuang Xiangtang High-tech Industrial Park Co-patentee after: Xinlitai (Chengdu) Biotechnology Co.,Ltd. Patentee after: Xinlitai (Suzhou) Pharmaceutical Co.,Ltd. Address before: Shaxi town of Suzhou City, Jiangsu province 215425 Guizhuang Xiangtang High-tech Industrial Park Co-patentee before: CHENGDU JINKAI BIOLOGICAL TECHNOLOGY Co.,Ltd. Patentee before: SUZHOU GENEMEN BIOTECH Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090930 Termination date: 20210722 |